Overview

This trial is active, not recruiting.

Conditions hiv, substance use
Treatments life steps-drug use, general health education
Phase phase 1
Sponsor Rhode Island Hospital
Start date July 2015
End date September 2019
Trial size 132 participants
Trial identifier NCT02907697, K23DA039037

Summary

Many people living with HIV use illicit drugs, which leads to worsened health outcomes and increased transmission of HIV due to poor adherence to medication regimens. This research will develop an intervention targeting medication adherence that is tailored to the unique needs of HIV-infected drug users. This research will promote adherence and improve treatment outcomes among HIV-infected drug users thereby minimizing the development of drug resistant strains of HIV and reducing transmission.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
The investigators expect the LifeSteps-Drug Use adaptation will be modeled after the Life Steps adherence intervention with the addition of a Drug Use module based on motivational interviewing and the FRAMES approach. The LifeSteps-Drug Use intervention is expected to include two in-person sessions and two telephone booster sessions. While anticipated preliminary adaptations have been based on the extant literature, changes to the protocol will be based on data obtained during the qualitative phase which will be sufficiently broad and open to assess for factors that we have not anticipated.
life steps-drug use
(Active Comparator)
The health education condition is a time-matched, active control arm. It will consist of two in-person sessions and two telephone sessions. Each session will cover a general health education topic.
general health education

Primary Outcomes

Measure
Antiretroviral Adherence
time frame: 1-, 3-, and 6-months

Secondary Outcomes

Measure
Center for Epidemiologic Studies Depression Scale (CES-D)
time frame: 1-, 3-, and 6-months
HIV Treatment Adherence Self-Efficacy (HIV-ASES)
time frame: 1-, 3-, and 6-months
U.S. Health Resources and Service Administration measure of HIV treatment retention
time frame: 1-, 6-months
Risk Assessment Battery
time frame: 1-, 3-, and 6-months
HIV1 Ultra RT PCR-Roche test
time frame: 1-, 3-, and 6-months
Urine Toxicology Screens
time frame: 1-, 3-, and 6-months
ACTG Self-Reported Antiretroviral Medication Adherence
time frame: 1-, 3-, and 6-months
30-day Timeline Followback (TLFB)
time frame: 1-, 3-, and 6-months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - over 18 years of age - HIV-infected - prescribed an antiretroviral regimen - meet DSM-V criteria for a substance use disorder (other than tobacco and alcohol) and report ≥3 days of use of an illicit drug per month over the past 90 days. - self-report <100% adherence and have experienced a detectable viral load (>20 copies/mL) within the last 6 months. Exclusion Criteria: - cognitive impairments that jeopardize informed consent - active psychosis - current suicidal ideation - not fluent in English - have a prescription for and report only medicinal use of marijuana

Additional Information

Official title Adherence Intervention for HIV-infected Drug Users
Principal investigator Kasey Claborn, PhD
Description This K23 research and training award advances the long-term goal of improving treatment outcomes and reducing transmission of HIV among HIV-infected drug users. The proposed training and research plans will enable the PI to develop the skills needed for an independent research career in the area of illicit drug use and HIV adherence intervention. The objective of this award is to develop skills in implementation science, behavioral intervention development and evaluation with drug using populations, and in-depth qualitative data analysis to accelerate refinement and effective implementation of interventions for HIV-infected drug users. Multiple comorbidities such as drug use and HIV act synergistically to produce poorer health outcomes and increase morbidity, mortality, and transmission of HIV. Consequently, effective and sustainable interventions adapted to drug users to improve antiretroviral medication adherence and reduce risk behaviors are urgently needed. Drug users present unique treatment challenges compared with other HIV-infected populations, including lower rates of adherence and inferior treatment outcomes. Additionally, interpersonal factors, including social support, negative patient-provider interactions, and socioeconomic challenges present significant barriers to adherence. Thus, the generalizability of current adherence interventions to drug users is limited, and there is a pressing need for efficacious interventions adapted to HIV-infected drug using populations. This project addresses this gap by being the first to adapt and test the acceptability and efficacy of a combined adherence and brief motivational intervention for HIV-infected drug users. Specifically, the intervention will augment the established Life Steps adherence intervention to include: (1) a tailored Life Steps module addressing the unique needs of illicit drug users, aimed at improving medication adherence; (2) a brief Motivational Interview to address drug use and other risk behaviors; and (3) two follow-up booster sessions. A three-phase, top-down research approach to adapt, refine, and pilot test the intervention will be conducted. Phase 1 will include focus groups with HIV-infected drug users currently prescribed antiretroviral medications and individual interviews with community-based clinicians. Phase 2 will include manual development, therapist training, a pilot trial, in-depth qualitative interviews, and further manual revisions. Phase 3 will include a small, 2-armed (intervention vs. health education control) randomized controlled trial with 60 HIV-infected drug users. Feasibility, acceptability, and preliminary indication of improvement in antiretroviral adherence and reduction in drug use will be examined at 1-, 3-, and 6-month follow-ups. To enable the PI to pursue this long-term research agenda, she will work with experienced mentors to build three areas of expertise: (1) proficiency in qualitative research methods and analysis; (2) skills in intervention development and evaluation with illicit drug using populations; (3) expertise in advanced longitudinal data analysis; and (4) implementation science. This K23 study addresses a key priority in HIV treatment science, and it will fully prepare the PI for an independent research career as an HIV intervention scientist.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Rhode Island Hospital.